Jim Wassil Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the transaction, the chief operating officer now directly owns 154,931 shares in the company, valued at approximately $11,351,794.37. This represents a 4.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Jim Wassil also recently made the following trade(s):

• On Monday, February 3rd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $86.22, for a total transaction of $689,760.00.
• On Thursday, January 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $83.66, for a total transaction of $669,280.00.

Vaxcyte Trading Down 2.6 %

NASDAQ PCVX opened at $70.24 on Wednesday. The company has a fifty day simple moving average of $83.98 and a 200 day simple moving average of $94.85. Vaxcyte, Inc. has a 12-month low of $58.10 and a 12-month high of $121.06. The company has a market cap of $9.04 billion, a P/E ratio of -15.27 and a beta of 0.98.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.14. Sell-side analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PCVX. Whipplewood Advisors LLC purchased a new stake in Vaxcyte in the 4th quarter valued at $28,000. Smartleaf Asset Management LLC grew its stake in shares of Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after acquiring an additional 260 shares in the last quarter. National Bank of Canada FI purchased a new stake in shares of Vaxcyte in the fourth quarter valued at about $41,000. Blue Trust Inc. lifted its position in shares of Vaxcyte by 100.0% during the fourth quarter. Blue Trust Inc. now owns 742 shares of the company’s stock valued at $61,000 after purchasing an additional 371 shares in the last quarter. Finally, Assetmark Inc. boosted its holdings in Vaxcyte by 77,500.0% during the fourth quarter. Assetmark Inc. now owns 776 shares of the company’s stock worth $64,000 after purchasing an additional 775 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on PCVX shares. Guggenheim reiterated a “buy” rating and set a $160.00 price target on shares of Vaxcyte in a report on Wednesday, February 26th. The Goldman Sachs Group began coverage on Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 target price for the company. Needham & Company LLC restated a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a report on Wednesday, February 26th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Wednesday, November 6th. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.